Galmed Pharmaceuticals Ltd. SEC filings EOCN
Galmed Pharmaceuticals Ltd. has 381 filings in SEC EDGAR's recent list, going back to Dec 31, 2013. Its latest annual report, Form 20-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 9, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 3, 2026 | — |
| POS EX | Filing | Jun 8, 2026 | — |
| EFFECT | Filing | Apr 1, 2026 | — |
| EFFECT | Filing | Sep 2, 2025 | — |
| EFFECT | Filing | Sep 2, 2025 | — |
| EFFECT | Filing | Aug 21, 2025 | — |
| CORRESP | Letter to the SEC | Aug 21, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2025 | — |
| EFFECT | Filing | Apr 8, 2025 | — |
| EFFECT | Filing | Nov 21, 2024 | — |
| CORRESP | Letter to the SEC | Nov 20, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 19, 2024 | — |
| EFFECT | Filing | Oct 28, 2024 | — |
| CORRESP | Letter to the SEC | Oct 28, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2024 | — |
| EFFECT | Filing | Sep 9, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 9, 2024 | — |
| CORRESP | Letter to the SEC | Sep 9, 2024 | — |
| EFFECT | Filing | Nov 29, 2023 | — |
| EFFECT | Filing | Jul 14, 2023 | — |
| CORRESP | Letter to the SEC | Jul 12, 2023 | — |
| CORRESP | Letter to the SEC | Jul 12, 2023 | — |
| EFFECT | Filing | Apr 1, 2021 | — |
| CORRESP | Letter to the SEC | Apr 1, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2021 | — |
| EFFECT | Filing | Apr 2, 2018 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2018 | — |
| CORRESP | Letter to the SEC | Apr 2, 2018 | — |
| D | Filing | Aug 15, 2017 | — |
| POS EX | Filing | Aug 4, 2017 | — |
| EFFECT | Filing | Jul 1, 2015 | — |
| CORRESP | Letter to the SEC | Jun 29, 2015 | — |
| CT ORDER | Filing | Jun 19, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 3, 2015 | — |
| EFFECT | Filing | Mar 12, 2014 | — |
| CERTNAS | Auto-generated paper document | Mar 11, 2014 | — |
| CORRESP | Letter to the SEC | Mar 11, 2014 | — |
| CORRESP | Letter to the SEC | Mar 11, 2014 | — |
| CORRESP | Letter to the SEC | Mar 11, 2014 | — |
| 8-A12B | Filing | Mar 11, 2014 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2014 | — |
| 424A | Filing | Mar 3, 2014 | — |
| CORRESP | Letter to the SEC | Feb 28, 2014 | — |
| UPLOAD | Letter from the SEC | Feb 24, 2014 | — |
| DRSLTR | Filing | Feb 6, 2014 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2014 | — |
| DRS | Filing | Dec 31, 2013 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EOCN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1595353
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.